MedTrace Logo

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

NCT04814368 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-10-24

Study results available
· View outcomes & findings →

Summary

The study was established to show safety and efficacy of canakinumab and LNA043 in patients with knee osteoarthritis (OA).

Conditions

Interventions

BIOLOGICAL

canakinumab

Canakinumab 600 mg single intra-articular injection (into the knee) on Day 1

BIOLOGICAL

LNA043

LNA043 40 mg intra-articular injection (into the knee) every 4 weeks, on Days 15, 43 and 71

OTHER

Placebo to canakinumab

Placebo to canakinumab single intra-articular injection (into the knee) on Day 1

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-27
Primary Completion
2024-06-24
Completion
2024-06-24
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Estonia
  • Hungary
  • Latvia
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814368 on ClinicalTrials.gov